Thomas Woiwode
CIK 1619294 · last filed 2023-05-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRSP price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1650
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PASG | Director | 35,418 | $3.36 | $119.0K | $4.05M | 5 | 2023-05-26 |
| ALGS | Director | 58,495 | $4.65 | $272.0K | $3.00M | 5 | 2022-06-27 |
| TPST | Director | 90,084 | $0.51 | $46.0K | $5.00M | 5 | 2022-06-22 |
| Gritstone bio, Inc. (GRTS) Delisted | Director | 6,740 | $0.03 | $217 | $5.00M | 5 | 2021-08-27 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | Director | 1,882 | $4.36 | $8.2K | $0 | 14 | 2021-05-14 |
| CRSP | Director | 645,643 | $49.01 | $31.64M | -$27.67M | 7 | 2018-06-15 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | 4,959 | — | — | $2.15M | 6 | 2017-12-27 |
| BOLD | Director | 6,811 | $2.41 | $16.4K | $525.0K | 2 | 2016-08-25 |
Recent Filings · Page 5 of 5
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-02-02 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | +3,449 | $0 | EDGAR |
| 2017-01-03 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | +3,449 | $0 | EDGAR |
| 2016-12-23 | CRISPR Therapeutics AG (PZRX) Delisted | Mixed | +6,669,699 | $2.25M | EDGAR |
| 2016-12-01 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | +3,509 | $0 | EDGAR |
| 2016-11-01 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | +3,390 | $0 | EDGAR |
| 2016-10-20 | CRISPR Therapeutics AG (PZRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-08-25 | BOLD | Grant (A) | — | $0 | EDGAR |
| 2016-07-25 | BOLD | Mixed | +1,806,832 | $525.0K | EDGAR |
| 2016-07-01 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | +24,155 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.